Fundraising Fox

Myeloid Therapeutics

3 known investors

myeloidtx.com ↗

CREATE Medicines develops in vivo CAR immunotherapy using proprietary mRNA-LNP technology to program T cells, NK cells, and myeloid cells directly within the body for cancer, autoimmunity, and fibrosis. The company's multi-immune platform enables off-the-shelf therapies with repeat dosing capability.

AI & Machine LearningBiotechHealthtechMedical Devicesin /createmedicines@CREATEMedicines

Investors · 3

ARCH Venture PartnersChicago
Hatteras Venture PartnersreportedResearch Triangle
Newpath PartnersreportedBoston

In the news